miRNA 的进展：一项技术评估

基于 RNA 的治疗和诊断研究的加速以及人类基因组测序的进步，使人们对 miRNA 在生物通路中的作用以及治疗和诊断应用的潜力有了更深入的了解。. miRNA 诊断的成功临床验证为 miRNA 诊断製造商创造了许多机会。 miRNA 作为循环生物标誌物的功能能够从体液中进行诊断。正在探索 miRNA 生物标誌物在识别甲状腺癌、乳腺癌和卵巢癌等疾病方面的潜力。 miRNA 诊断技术进一步发展，被视为有前景的即时诊断技术。

本报告将重点关注 miRNA 治疗和诊断的发展。我们还探讨了推动 miRNA 研究兴趣的因素以及影响 miRNA 治疗和诊断学商业化的因素，同时还讨论了 miRNA 技术公司的新机遇，并为行业和利益相关者提供见解。总结您的投资前景。

内容

战略要务

• 为什么增长变得越来越困难，战略势在必行 8(TM)：miRNA 技术增长驱动力
• 战略要务
• 三大战略要务对 miRNA 行业的影响
• 增长机会加速增长管道引擎

增长机会分析

• 分析范围
• 细分
• 增长驱动力
• 抑制增长的因素

评估 miRNA 治疗前景：简介

评估 miRNA 治疗前景：应用

评估 miRNA 治疗前景：递送和稳定性

miRNA 诊断领域的评估：简介

miRNA 诊断领域的评估：应用

评估 miRNA 治疗和诊断：资金前景

增长机会

• 增长机会 1：改进靶向给药系统以减少脱靶效应和毒性
• 增长机会 2：开发 POC 诊断技术以检测跨疾病的循环生物标誌物
• 增长机会 3：精准医疗的伴随诊断

附录

下一步

Developments in miRNA sequencing and analysis are driving future growth potential in therapeutics and diagnostics

Accelerated research around RNA-based therapeutics and diagnostics, accompanied by technology advancements in sequencing the human genome, has resulted in a better understanding of the role of miRNA in biological pathways, enhancing its potential in both therapeutics and diagnostics. The successful clinical validation of miRNA diagnostic tests has created several opportunities for miRNA diagnostic companies. The role of miRNAs as circulating biomarkers makes it possible to perform diagnostics from body fluids. The potential of miRNA biomarkers in identifying diseases like thyroid cancer, breast cancer, and ovarian cancer is being explored. miRNA diagnostics is expected to grow further and become prominent in point-of-care diagnostics. The development of miRNA therapeutics has had its challenges with respect to stability and delivery issues. However, newer approaches in the development of antagomiRs (miRNA inhibiting drugs) and agomiRs (miRNA replacement therapy) have shown promising results. miRNA companies have witnessed a highly competitive ecosystem and have been acquired by several larger pharma and diagnostics companies upon their entry into the clinical trial stage.

This study focuses on the developments in miRNA therapeutics and diagnostics. It identifies the factors driving interest in miRNA research as well as those affecting the commercialization of miRNA therapeutics and diagnostics. The report also discusses the emerging opportunities for miRNA technology companies and highlights investment prospects for industry participants and stakeholders.

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on miRNA Technology Growth
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Micro Ribonucleic Acid (miRNA) Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation
• Growth Drivers
• Growth Restraints

Assessment of miRNA Therapeutics Landscape: Introduction

• Emerging Trends in miRNA Therapeutics and Diagnostics
• Increasing Research in miRNA Therapeutics and Diagnostics
• miRNA Drugs Experiencing Rapid Strides in Clinical Development
• Enablers Accelerating miRNA Research and Commercial Development
• Introduction to miRNA Therapeutics
• miRNA Therapeutics to Address Complex Diseases
• Evolving Approaches in Developing Antagomirs and miRNA Mimics
• Structural Modifications to Increase miRNA Stability

Assessment of miRNA Therapeutics Landscape: Application

• Application of miRNAs in Diseases
• Oncology
• Respiratory Diseases
• Neurology
• Cardiovascular Diseases
• Other Diseases
• Other Diseases
• miRNA Therapeutics in Development by Companies
• Increasing miRNA Research Activities in Academia

Assessment of miRNA Therapeutics Landscape: Delivery and Stability

• Challenges in miRNA Therapeutics
• Important miRNA Therapeutics Delivery Systems
• Comparison of miRNA Delivery Systems
• Developing Newer Delivery Systems
• Future Prospects of miRNA Therapeutics

Assessment of miRNA Diagnostics Landscape: Introduction

• Introduction to miRNA Diagnostics
• Benefits of miRNA Diagnostics
• Opportunities for Using miRNA in Diagnostics
• Emerging Developments in miRNA Diagnostics

Assessment of miRNA Diagnostics Landscape: Application

• Oncology
• Neurological Diseases
• Cardiovascular and Other Diseases

Assessment of miRNA Therapeutics & Diagnostics: Funding Landscape

• M&A miRNA Therapeutics
• M&A miRNA Diagnostics
• Funding Landscape of miRNA companies
• miRNA-Important Takeaways
• miRNA-Important Takeaways

Growth Opportunity Universe

• Growth Opportunity 1: Improved Targeted Delivery Systems to Reduce Off-target Effects and Toxicity
• Growth Opportunity 1: Improved Targeted Delivery Systems to Reduce Off-target Effects and Toxicity (continued)
• Growth Opportunity 2:Development of POC Diagnostics to Detect Circulating Biomarkers Across Diseases
• Growth Opportunity 2: Development of POC Diagnostics to Detect Circulating Biomarkers Across Diseases (continued)
• Growth Opportunity 3: Companion Diagnostics for Precision Medicine
• Growth Opportunity 3: Companion Diagnostics for Precision Medicine (continued)

Appendix

• Technology Readiness Levels (TRL): Explanation
• Funding Landscape for miRNA Therapeutics
• Funding Landscape for miRNA Therapeutics (continued)
• Funding Landscape for miRNA Diagnostics

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer